BRAF K601E Mutation in Oncocytic Carcinoma of the Thyroid: A Case Report and Literature Review.
증례보고
1/5 보강
[BACKGROUND] Thyroid carcinoma (TC) is the most common endocrine cancer, with papillary thyroid carcinoma (PTC) being the most common subtype.
APA
Matrone A, Citro F, et al. (2023). BRAF K601E Mutation in Oncocytic Carcinoma of the Thyroid: A Case Report and Literature Review.. Journal of clinical medicine, 12(22). https://doi.org/10.3390/jcm12226970
MLA
Matrone A, et al.. "BRAF K601E Mutation in Oncocytic Carcinoma of the Thyroid: A Case Report and Literature Review.." Journal of clinical medicine, vol. 12, no. 22, 2023.
PMID
38002585
Abstract
[BACKGROUND] Thyroid carcinoma (TC) is the most common endocrine cancer, with papillary thyroid carcinoma (PTC) being the most common subtype. BRAF and RAS oncogene were characterized as the most frequently altered genes in PTC, with a strong association between genotype and histotype. The most common mutation in BRAF gene is V600E and is prevalent in classic and aggressive variants of PTC, while BRAF K601E mutation is the most common among the other rare BRAF mutations. BRAF K601E mutated thyroid carcinomas are usually characterized by low aggressiveness, except for anecdotal cases of poorly differentiated TC.
[CASE PRESENTATION] We described a case of oncocytic carcinoma of the thyroid (OCA) with an aggressive clinical course, including widespread metastasis and resistance to radioiodine treatment. Molecular analysis revealed the exclusive presence of the BRAF K601E mutation in both primary tumor and metastatic lesions. Accordingly, a revision of the literature about aggressive TC cases carrying BRAF K601E mutation was performed.
[CONCLUSION] Although rare, this case emphasizes the relevance of considering BRAF K601E mutation in advanced non-PTC thyroid carcinomas, since it can be considered an actionable mutation for target therapies.
[CASE PRESENTATION] We described a case of oncocytic carcinoma of the thyroid (OCA) with an aggressive clinical course, including widespread metastasis and resistance to radioiodine treatment. Molecular analysis revealed the exclusive presence of the BRAF K601E mutation in both primary tumor and metastatic lesions. Accordingly, a revision of the literature about aggressive TC cases carrying BRAF K601E mutation was performed.
[CONCLUSION] Although rare, this case emphasizes the relevance of considering BRAF K601E mutation in advanced non-PTC thyroid carcinomas, since it can be considered an actionable mutation for target therapies.
같은 제1저자의 인용 많은 논문 (5)
- Fatal tracheal perforation following Dabrafenib-Trametinib therapy in V600E-mutant mixed anaplastic thyroid cancer.
- Timing and Ideal Patient for an Appropriate Search for Somatic Mutation in Medullary Thyroid Cancer.
- Erectile Dysfunction in Patients Treated with Selpercatinib for -Altered Thyroid Cancer.
- Long-Term Outcome of Patients with Low-Risk Differentiated Thyroid Cancer Treated with Total Thyroidectomy Alone.
- Risk factors in thyroid cancer: is the obesity pandemic an important factor?